Content Detail

• Content META

  Title	Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20?
  ID	3061517
  External ID	152355494
  Author
  Published Date	Oct. 8, 2024, 10:23 a.m.
  Summary	Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20? Ramish Cheema Tue, Oct 8, 2024, 11:23 PM 8 min read In This Article: VTRS +0.80% We recently made a list of 10 Best NASDAQ Stocks Under $
  Tags	None
  URL	No URL
  Sentiment	Negative: 0.83870    Neutral: 0.03969    Positive: 0.12161
  Relevance	0.02564

• Content Details

  Content ID	1515045
  Key	307f13c9-324f-4616-8d59-e9d1b892f9c0
  Content	Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20? Ramish Cheema Tue, Oct 8, 2024, 11:23 PM 8 min read In This Article: VTRS +0.80% We recently made a list of 10 Best NASDAQ Stocks Under $20 to Buy . In this piece, we will look at where Viatris Inc. (NASDAQ:VTRS) ranks among the list of the best NASDAQ stocks under $20. The close of September has seen the much awaited interest rate cut from the Federal Reserve materialize. The Fed, in a move that surprised some market participants, decided to cut rates by 50 basis points in the third week of September. Investors’ surprise surrounding this decision was clear as major indexes fell in the immediate aftermath of the rate cut and ended the day lower. This was because an outsized rate cut stoked fears about the health of the economy, which tends to make the US dollar stronger and hurt equity returns. However, the next day would see a complete reversal. Bullish investors made sure that the benchmark S&P stock index closed at a new record high – its first in two months which has seen investors reckon with a weak labor market to contend whether it signaled an incoming recession. The day after the rate cut, the benchmark S&P index gained 1.70% and closed the day at a new record of 5,713 points. However, its percentage gains during the day would be eclipsed by the broader NASDAQ stock index, as it was up by 2.61%. The week’s end would see the S&P, the NASDAQ, and the Dow close with 1.36%, 1.49%, and 1.62%, respectively. Yet, even though indexes closed higher in a month that is typically bearish for stocks, Friday’s trading saw the NASDAQ trim 0.36% over the previous day while the S&P ended 0.19% lower. This end of the week uncertainty underpins the sentiment that should mark stock returns for October. In October, investors will reckon with a hotly contested election and try to decipher whether the third quarter earnings season makes stocks more attractive. With the benchmark S&P trading at a forward price to earnings ratio of 21 which is 34% higher than its long term average of 15.7, there appears to be limited room for further gains in equities unless the corporate sector smashes earnings out of the park. This overvaluation in markets is also evident in the price to book value ratio, as equities are currently trading at 5x, which is nearly double their long term average of 2.6x. Consequently, the bullishness that investors have had prior to the interest rate cutting cycle makes us wonder whether large cap stocks can deliver more returns. The technology sector as a whole has been led by the world’s leading artificial intelligence graphics processing unit (AI GPU) designer whose shares are up 141% year to date. Yet, the uneasiness that investors are feeling is apparent as well. This same stock had gained 181% by the second week of June, with concerns of a product delay, weaker margins, and tepid guidance making it pull back and lose 27% by the first week of August which also greeted investors with weak labor market data. Its gains have also pushed the broader NASDAQ index in 2024 which is up by 22.74% year to date. Using a NASDAQ ETF by Fidelity as a proxy, we find out that the top five stocks in the ETF account for roughly 44% of the total holdings. These five stocks, starting from the fifth, are up by 62%, 27.8%, 141%, 17.36%, and 22.9%. This makes it clear that the biggest holdings of the index have driven its returns. This bifurcation in the stock market has been on the minds of investment banks as well. As we noted in our coverage of Morgan Stanley’s Highest Conviction Stocks: Top 20 Stocks To Buy , the banks’ analysts had noted that there “is ample room for equities performance to broaden, but this requires a cyclical recovery,” adding that the market cap based difference in the benchmark S&P’s returns was clear as the forward P/E “runs at 21x on a cap-weighted basis but only 16x equal- weighted.” However, they cautioned that the potential to benefit from this gap via investing in small cap stocks “requires economic growth acceleration with lower interest rates, which seems unlikely in the current inflation environment.” This return has fluctuated with bond yields in the past. Data compiled by MS shows that historically at 1% levels for bond yields, small cap stocks returned 100% relative to large caps. On the flip side, as yields soared to ~5.6%, this metric dropped to 82%. Yet, even though MS might have been cautious for small caps before the Fed’s interest rate cut, the undervaluation in small caps is supported by other data points too. For instance, JPMorgan shares that for small and medium cap (SMID) and large cap stocks that are the top 20% in terms of free cash flow margins, the forward P/E ratio of the SMID stocks relative to the large cap stocks was 0.74x as of April 2024. This marks a sizeable difference over its peak of 1.38x in April 2009. Similarly, if we consider the forward P/E ratios of small cap over large cap stocks as a whole, we find out that as of May 2024, they were trading at 73%, which is quite low over a high of approximately 125% after 2010. Cycling back to MS’ belief that small cap stock performance is dependent on the economy, data shows that as the economy recovers from a recession, small caps delivered 9.62% in returns historically starting from 1984. This is 0.66% higher than the large cap returns of 8.97%, and the gap widens during economic expansion. In this phase of the business cycle, small caps delivered 25.5% in returns, while the large cap returns were 20.57%. Similarly, extrapolating this analysis to the Fed’s rate cut cycles by running a regression with the small to large cap returns as a function of rate changes shows that the rate changes have a beta of -4.39. This means that reducing rates leads to a higher spread and indicates that lower rates do prime up small caps for gains provided that economic performance is robust. Our Methodology To make our list of the best NASDAQ stocks under $20 to buy, we ranked the 100 most valuable stocks on the NASDAQ that had a share price lower than $20 by their market capitalization and picked out the stocks with the highest number of hedge fund investors in Q2 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. ( see more details here ). A broker in a trading room surrounded by screens, representing the stock market. Viatris Inc. (NASDAQ: VTRS ) Number of Hedge Fund Holders In Q2 2024: 45 Share Price: $11.56 Viatris Inc. (NASDAQ:VTRS) is a sizeable pharmaceutical company that sells generic drugs, raw materials to make medicine, biologically similar drugs to well known treatments, and other associated products. Its product portfolio coupled with a global market presence provides the firm exposure to several markets to hedge against country specific downturns. It also allows the company to earn revenue during economic downturns and utilize economies of scale by selling generics. Viatris Inc. (NASDAQ:VTRS)’s significant financial resources, as evidenced by its cash and equivalents of $1.1 billion and receivables of $4 billion also allow the firm to acquire commercialization rights to lucrative assets by enabling small firms to bring their drugs to the market. Two such treatments that the firm has recently gotten hold of are cenerimod which is being developed to treat lupus and selatogrel for heart attacks. The two drugs are in phase three trials, and strong performance coupled with regulatory approval could create tailwinds for Viatris Inc. (NASDAQ:VTRS)’s shares. Such acquisitions are key for the firm as its business lacks differentiation and forces it to compete on the basis of costs. Viatris Inc. (NASDAQ:VTRS)’s management has been busy raising cash by divesting some businesses. Here’s what it had to say during the Q2 2024 earnings call : “Free cash flow for the quarter was primarily impacted by lower adjusted EBITDA due to the closing of divestitures. Our free cash flow and existing cash on hand allowed us to strengthen our balance sheet with debt paydown of approximately $800 million in the quarter. And as we look towards the rest of the year, we expect to have in excess of $3 billion in cash available for deployment. This takes into account divestiture proceeds received in the third quarter, expected divestiture costs and our latest outlook for free cash flow. We expect the significant financial flexibility will allow us to pay down additional debt to reach our long-term gross leverage target of approximately three times by the end of the year. We also expect to return capital in the form of dividends and will remain opportunistic with potential share repurchases and business development activity.” Overall VTRS ranks 5th on our list of the best NASDAQ stocks under $20. While we acknowledge the potential of VTRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than VTRS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’ . Disclosure: None. This article was originally published on Insider Monkey . All investment decisions should be made after consulting a qualified professional. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories
  Content Reference URL	None

• Publisher

  None

• Data Source

  Data Source Name	Yahoo Finance News
  Data Source Type	news
  Data Source URL	https://finance.yahoo.com/
  Description	Yahoo! Finance is a media property that is part of the Yahoo! network. It provides financial news, data and commentary including stock quotes, press releases, financial reports, and original content. It also offers some online tools for personal finance management.
  Weight	10